Ocular involvement in Behçet's syndrome still represents a challenge for both
rheumatologists and ophthalmologists; over the past 20 years the availability of new …

Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD),
which tends to respond poorly to different medications. The ocular histopathologic changes …

Background Little is known about the relationship between the disease activity of Behçet
disease (BD) and the incidence of inflammatory major organ events. Objectives In this …

Purpose: To evaluate the effectiveness of biologic therapy in a cohort of patients with various
types of refractory non-infectious uveitis and scleritis. Methods: A retrospective observational …

Uveitis is one of the most common causes of vision loss and blindness worldwide. Local
and/or systemic immunosuppression is often required to treat ocular inflammation in …

Purpose To evaluate the efficacy and safety of adalimumab (ADA, Humira®) for treatment of
non-infectious uveitis (NIU) refractory to conventional medications. Methods Anti-tumor …

Introduction To evaluate the efficacy of SB5, an adalimumab biosimilar, in the management
of Behçet's syndrome (BS)-related uveitis. Methods Data from eight BS patients (16 eyes) …

Introduction: The efficacy of anti-TNFα agents has been recently evaluated in many studies
in Behçet's disease (BD), particularly in ocular and life-threatening manifestations such as …

Objective: The objective of this study was to investigate the effectiveness and safety of
interferon (IFN) α2a as an add-on treatment for refractory Behçet's uveitis (BU). Methods: In …

Objective. To assess the efficacy of monoclonal anti-tumour necrosis factor (TNF)-α agents
in patients with anterior uveitis (AU) in terms of decrease of recurrences, variation of visual …